Videos

Ira Zackon, MD, discusses the real-world uptake of bispecific antibodies in community oncology practices and what it reveals about their utilization in relapsed/refractory multiple myeloma treatment.

Elizabeth A. Brem, MD, discusses treatment options for patients with diffuse large B-cell lymphoma.

Julio Chavez, MD, MS, discusses some of the important studies and research being presented at the 2024 American Society of Hematology Annual Meeting and Exposition.

Fatima Tuz Zahra, MD, discusses the methods and design of a retrospective analysis of 65 patients with acute myeloid leukemia treated with oral azacitidine maintenance after achieving complete remission.

Samer A. Al’Hadidi, MD, discusses the importance of personalized medicine in patients with multiple myeloma.

Palak Dave discusses the diagnostic challenges between myelodysplastic syndrome and pre-MDS conditions.

Akriti Jain, MD, discusses what she is most looking forward to seeing presented at the upcoming 2024 American Society of Hematology Annual Meeting and Exposition.

Panelist discusses how the RRMM treatment landscape has evolved significantly, with BiTEs emerging as a promising approach. BCMA-targeted BiTEs showed efficacy, while GPRC5D-targeting agents like talquetamab represent promising new options, particularly for patients with BCMA-refractory disease. Key challenges include managing cytokine release syndrome, developing optimal sequencing strategies, addressing drug resistance, and improving accessibility and affordability of novel therapies.

Panelist discusses the clinical patient, a 72-year-old man who was previously diagnosed 6 years ago with multiple myeloma, 60% plasma cells, which he presents to his oncologist after 5 prior treatment regimens. The patient also has had 2 episodes of pneumonia and multiple episodes of bronchitis over the prior 10 years.

Paulina Velasquez, MD, discusses the differences between T-cell receptor-based and chimeric antigen receptor T-cell therapies.

Evan Lipson, MD, discusses the evolving treatment landscape for advanced melanoma.

Francis P. Worden, MD, discusses how the effectiveness of lenvatinib in this real-world setting compares with results from other clinical trials.

Bertrand Y. Tuan, MD, discusses the therapies relevant to patients with low-risk myelodysplastic syndrome.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the results and potential impact from the phase 3 CEPHEUS trial.

Targeted Oncology co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for community oncologists to look out for at the upcoming ASH Annual Meeting in San Diego, with some additional tidbits to round out the main event.

Joe DePinto, MBA, discusses the complexity of the cell and gene therapy ecosystem and the need for collaboration with partners to support it effectively.

Susan L. Slager, PhD, discusses some of the recommendations for genetic testing in individuals with a family history of chronic lymphocytic leukemia.

Barbara O’Brien, MD, discusses the next steps of the phase 2 TBCRC049 study for the treatment of patients with HER2-positive breast cancer and leptomeningeal metastasis.

Susan L. Slager, PhD, discusses the use of polygenic risk scoring to assess individual risk for CLL.

Sarah Sammons, MD, discusses some of the challenges seen with different regimens for HER2-positive metastatic breast cancer treatment

Reid Merryman, MD, discusses which patients are typically monitored for minimal residual disease and whether there are specific subtypes or stages where the assessment is particularly critical.

Domenica Lorusso, MD, PhD, discusses the rationale behind the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.

Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with relapsed/refractory multiple myeloma.

Susan L. Slager, PhD, discusses the background of her research on inherited germline genetics for risk of chronic lymphocytic leukemia.

Oleg Gligich, MD, discusses utilizing circulating tumor DNA to assess patients with lung cancer.

Along with the Oncology Brothers, Paolo Tarantino, MD, discusses ongoing studies investigating oral selective estrogen receptor degraders, including trials exploring use of elacestrant in combination with other therapies.

Along with the Oncology Brothers, Paolo Tarantino, MD, discusses what has been learned about the safety profile of elacestrant and shares clinical pearls for adverse event management, aimed at helping patients remain on therapy while maximizing their quality of life.

Along with the Oncology Brothers, Paolo Tarantino, MD, discusses the post -hoc subgroup analysis from the EMERALD study (SABCS 2023), which examined outcomes in patients with ESR1 mutations (ESR1m) who had been on CDK4/6 inhibitors (CDK4/6i) plus endocrine therapy for 12 months or longer, and shares her his perspectives on how these findings may influence the use of elacestrant in ER+/HER2–- metastatic breast cancer (MBC) and impact clinical practice for community oncologists.

Along with the Oncology Brothers, Paolo Tarantino, MD, elaborates on results from an analysis of data from the EMERALD study that were reported at the San Antonio Breast Cancer Symposium (SABCS) 2022. This analysis identified duration of prior CDK4/6 inhibitor therapy as a potential surrogate marker for endocrine sensitivity, and discusses how these findings could help guide patient selection for elacestrant.

Along with the Oncology Brothers, Paolo Tarantino, MD, discusses how ESR1 mutations are commonly observed in hormone receptor-positive breast cancer after prolonged endocrine therapy, and emphasizes the importance of molecular testing for ESR1 mutations at both the initial diagnosis of MBC and at each subsequent progression using liquid biopsy assays.